The EU Commission, which works alongside competition authorities from member states, announced on Monday that it will allow the Danish state to offer Bavarian Nordic EUR 108m to support the development of its Covid-19 vaccine.
"This EUR 108m Danish aid measure will contribute to much needed research and development activities to respond to the coronavirus outbreak. We continue working in close cooperation with member states to find workable solutions to mitigate the economic impact of the coronavirus outbreak, in line with EU rules," says Margrethe Vestager, who is Executive Vice-President in charge of competition policy, in a press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Thousands of collaborative research papers with China pose threat to Europe, authorities worry
Research collaborations with China, including those in the life science sector, are being put under the microscope as defense authorities express concerns about Chinese espionage in Europe.
Orphazyme's creditors to vote on sales agreement at end of May
Sunday’s sales agreement between US-based Kempharm and Orphazyme will be decided on May 30, when the company’s creditors meet to vote on the proposal.
Novo Holdings establishes new firm managed by biotech veterans
Co-Founder and former CSO of Orphazyme Thomas Kirkegaard Jensen and Bo Rode Hansen, CEO of Scandion Oncology, are both involved in another secret venture backed by Novo Holdings.
Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic
Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Nordic Medical Affairs Manager 
Analytical Senior Scientist 
Clinical Project Manager 
Client Talent Acquisition Specialist 
Chemist for Incoming Materials in QC Department 
Senior QA Specialist 
Process Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
2 Sales Representatives and Product Specialists 
Project Manager & Scrum Master 
Account Manager 
Key Account Manager, Europe and Asia